Brenda Melendez

Brenda Melendez

Auto-generated profile, based on publicly available information

Brenda Melendez

Department of Genomic Medicine

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2025 in JCI Insight
Verified
Journal Article
Open access
PDF file
MBMikayla Borthwick Bowen
Mikayla Borthwick Bowen
BMBrenda Melendez
Brenda Melendez
QZQian Zhang
Qian Zhang
DMDiana Moreno
Diana Moreno
LPLeah Peralta
Leah Peralta
MYMelinda Yates
Melinda Yates
Lynch syndrome (LS), caused by inherited mutations in DNA mismatch repair genes, including MSH2 , carries a 60% lifetime risk of developing endometrial cancer (EC). Beyond hypermutability, mechanisms driving LS-associated EC (LS-EC) remain unclear. We investigated MSH2 loss in EC pathogenesis using a mouse model ( PR-Cre Msh2 LoxP/LoxP , abbreviated Msh2KO), primary cell lines, human tissues, and human EC cells with isogenic MSH2 knockdown. By 8 months, 58% of Msh2KO mice developed endometrial atypical hyperplasia (AH), a precancerous lesion. At 12–16 months, 50% of Msh2KO mice exhibited either AH or ECs with histologic similarities to human LS-ECs. Transcriptomic profiling of EC from Msh2KO mice revealed mitochondrial dysfunction–related pathway changes. Subsequent studies in vitro and in vivo revealed mitochondrial dysfunction based on 2 mechanisms: mitochondrial content reduction and structural disruptions in retained mitochondria. Human LS-ECs also exhibited mitochondrial content reduction compared with non-LS-ECs. Functional studies demonstrated metabolic reprogramming of MSH2-deficient EC, including reduced oxidative phosphorylation and increased susceptibility to glycolysis suppression. These findings identified mitochondrial dysfunction and metabolic disruption as consequences of MSH2 deficiency in EC. Mitochondrial and metabolic aberrations should be evaluated as biomarkers for endometrial carcinogenesis or risk stratification and represent potential targets for cancer interception in women with LS.